Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin

NCT00966914 is registered in ClinicalTrials.gov with BioNumerik Pharmaceuticals, Inc. as lead sponsor.

NCT NCT00966914
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00966914 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Multicenter, Double-blind, Phase 3 Trial of Tavocept Versus Placebo in Patients With Newly Diagnosed or Relapsed Advanced Primary Adenocarcinoma of the Lung Treated With Docetaxel or Paclitaxel Plus Cisplatin
Lead sponsor
BioNumerik Pharmaceuticals, Inc.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2010
Completion date
June 30, 2013
Enrollment
540 (actual)
Sites
42

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer